论文信息 - Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. - 字舞流文

Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.

A. Kamal | S. Mao | Jay Harper | P. Strout

[1] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[2] A. Younes,et al. Brentuximab Vedotin (SGN-35) , 2011, Clinical Cancer Research.

[3] G. Adams,et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. , 2011, Cancer research.

[4] Stephen C Alley,et al. Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.

[5] G. Frantz,et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. , 2009, Cancer research.

[6] John M Lambert,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[7] P. Carter,et al. Antibody-Drug Conjugates for Cancer Therapy , 2008, Cancer journal.

[8] B. van Deurs,et al. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. , 2004, Molecular biology of the cell.

[9] Laurent Ducry,et al. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.